Literature DB >> 27717004

Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes.

Jakob Werner Hansen1, Maj Karoline Westman2, Lene Dissing Sjö3, Leonie Saft4, Lasse Sommer Kristensen1, Andreas Due Ørskov1, Marianne Treppendahl1, Mette Klarskov Andersen2, Kirsten Grønbaek1.   

Abstract

Cytopenia is common in the elderly population and etiology may be difficult to assess. Here, we investigated the occurrence of mutations in patients with idiopathic cytopenia of undetermined significance and the usefulness in improving diagnostics. We included 60 patients with persistent cytopenia > 6 months without definite diagnosis of hematological neoplasm after routine assessment. Bone marrow material underwent a blinded morphology review and DNA was sequenced with a targeted 20 gene panel representing the most commonly mutated genes in myelodysplastic syndrome. Thirty seven (62%) patients carried at least one mutation at inclusion, and of these 95% carried a mutation in TET2, ASXL1, SRSF2, or DNMT3A. The most commonly mutated gene was TET2 observed in 43% of all patients. During one to eight years follow-up seven patients progressed to a myeloid neoplasm and six of these had a detectable mutation at study entry. Median time to progression was 53 months (range 10-78), and at time of progression each patient had at least two mutations detected. Mutations in TP53 and NRAS were not present in patients at inclusion, but identified as secondary hits triggering progression. The morphology review was concordant in 68% of all cases, and 93% of the cases reclassified into the group "highly suspicious for MDS" had a mutation. All patients who had a concordant review "highly suspicious for MDS" had at least two mutations detected. Overall, we show that morphology examination is challenging in this heterogeneous group and targeted sequencing helps identify patients at risk of progression. Am. J. Hematol. 91:1234-1238, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27717004     DOI: 10.1002/ajh.24554

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Getting personal with myelodysplastic syndromes: is now the right time?

Authors:  Nora Chokr; Alexander B Pine; Jan Philipp Bewersdorf; Rory M Shallis; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2019-04-12       Impact factor: 2.929

2.  Application of whole-exome sequencing to direct the specific functional testing and diagnosis of rare inherited bleeding disorders in patients from the Öresund Region, Scandinavia.

Authors:  Eva Leinøe; Eva Zetterberg; Savvas Kinalis; Olga Østrup; Peter Kampmann; Eva Norström; Nadine Andersson; Jenny Klintman; Klaus Qvortrup; Finn Cilius Nielsen; Maria Rossing
Journal:  Br J Haematol       Date:  2017-07-27       Impact factor: 6.998

3.  The diagnostic and prognostic role of flow cytometry in idiopathic and clonal cytopenia of undetermined significance (ICUS/CCUS): A single-center analysis of 79 patients.

Authors:  Konstantinos Dimopoulos; Olga Kristina Hansen; Lene Dissing Sjö; Leonie Saft; Ida Marianne Schjødt; Jakob Werner Hansen; Kirsten Grønbaek
Journal:  Cytometry B Clin Cytom       Date:  2019-09-03       Impact factor: 3.058

4.  TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells.

Authors:  Kasper D Rasmussen; Ivan Berest; Sandra Keβler; Koutarou Nishimura; Lucía Simón-Carrasco; George S Vassiliou; Marianne T Pedersen; Jesper Christensen; Judith B Zaugg; Kristian Helin
Journal:  Genome Res       Date:  2019-02-22       Impact factor: 9.043

5.  Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes.

Authors:  Amalie Bach Nielsen; Jakob Werner Hansen; Andreas Due Ørskov; Konstantinos Dimopoulos; Mohammad Salem; Mariam Grigorian; Helle Bruunsgaard; Kirsten Grønbæk
Journal:  Hemasphere       Date:  2022-04-22

6.  A predictive model for bone marrow disease in cytopenia based on noninvasive procedures.

Authors:  Dicte Træden; Morten Tulstrup; Jack Bernard Cowland; Lene Dissing Sjö; Martin Bøgsted; Kirsten Grønbæk; Mette Klarskov Andersen; Jakob Werner Hansen
Journal:  Blood Adv       Date:  2022-06-14

7.  Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes.

Authors:  Linn Gillberg; Andreas D Ørskov; Ammar Nasif; Hitoshi Ohtani; Zachary Madaj; Jakob W Hansen; Nicolas Rapin; Johanne B Mogensen; Minmin Liu; Inge H Dufva; Jens Lykkesfeldt; Petra Hajkova; Peter A Jones; Kirsten Grønbæk
Journal:  Clin Epigenetics       Date:  2019-10-17       Impact factor: 6.551

8.  Clonal Cytopenia of Undetermined Significance in a Patient with Congenital Wilms' Tumor 1 and Acquired DNMT3A Gene Mutations.

Authors:  Ken Murakami; Yuuta Yamaguchi; Yuko Kida; Yoichiro Morikawa; Hidetoshi Ujiie; Hiroyuki Sugahara; Yasuhito Nannya; Seishi Ogawa; Yuzuru Kanakura
Journal:  Intern Med       Date:  2021-05-29       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.